Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 5:27 AM ET

Company Overview of National Institute On Alcohol Abuse & Alcoholism

Company Overview

,  

United States

Key Executives for National Institute On Alcohol Abuse & Alcoholism

Compensation as of Fiscal Year 2014.

National Institute On Alcohol Abuse & Alcoholism Key Developments

XenoPort, Inc. and the National Institute on Alcohol Abuse & Alcoholism Announce Clinical Trial Agreement to Study Horizant as Potential Treatment for Alcohol Use Disorder

XenoPort, Inc. and the National Institute on Alcohol Abuse and Alcoholism announced that they have entered into an agreement to conduct a clinical trial of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT. XenoPort will have access to study results generated under the proposed clinical trial to support potential regulatory filings for HORIZANT. The study is planned to be a randomized, double-blind, placebo-controlled clinical trial of the safety and efficacy of HORIZANT in patients who have AUD but are abstinent at treatment initiation. The study is expected to have a treatment period of six months and to enroll approximately 350 patients beginning in the first half of 2015. XenoPort and the NIAAA are planning to meet with the U.S. Food and Drug Administration (FDA) Division of Anesthesia, Analgesia and Addiction Products in the fourth quarter of 2014 to discuss the trial design and the possibility of utilizing the results of this trial as the basis for a potential supplemental new drug application (sNDA) submission for HORIZANT for the maintenance of abstinence from heavy drinking of alcohol in patients with AUD.

NIH Names Dr. George Koob Director of the National Institute on Alcohol Abuse and Alcoholism

National Institutes of Health Director Francis S. Collins, M.D., Ph.D., announced the selection of George F. Koob, Ph.D., as Director of the National Institute on Alcohol Abuse and Alcoholism. Dr. Koob is expected to join the NIH in January 2014. As NIAAA director, Dr. Koob will oversee the institute’s $458 million budget, which primarily funds alcohol-related research in a wide range of scientific areas including genetics, neuroscience, epidemiology, prevention, and treatment. Dr. Koob comes to the NIH from The Scripps Research Institute, California Campus, where he is Chairman, Committee on the Neurobiology of Addictive Disorders, and Director, Alcohol Research Center.

Similar Private Companies By Industry

Company Name Region
Meyn America L.L.C. United States
MicaMatrix Corp. United States
Registered Plan Services Corporation United States
Optena Corporation United States
Coalsales II, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact National Institute On Alcohol Abuse & Alcoholism, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.